NMDA antagonist (IC50 = 11 μM for inhibition of [3H]MK-801 binding to rat forebrain membranes). Protects against NMDA- and quisqualate-induced neurotoxicity (EC50 = 3.8 μM) and enhances dopamine D1 receptor activity. Inhibits NF-κB, reducing TNF-α, IL-6 and nitric oxide production, and acts as a free radical scavenger. Exhibits beneficial effects in experimental models of multiple sclerosis, bacterial meningitis, septic shock, epilepsy, and traumatic and ischemic brain injury. Brain penetrant.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 386.57. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.59 mL||12.93 mL||25.87 mL|
|5 mM||0.52 mL||2.59 mL||5.17 mL|
|10 mM||0.26 mL||1.29 mL||2.59 mL|
|50 mM||0.05 mL||0.26 mL||0.52 mL|
References are publications that support the biological activity of the product.
Eshhar et al (1993) HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. Neuroreport 5 237 PMID: 8298080
Striem et al (1997) Interaction of dexanabinol (HU-211), a novel NMDA receptor antagonist, with the dopaminergic system. Eur.J.Pharmacol. 338 205 PMID: 9424014
Gallily et al (1997) Protection against septic shock and suppression of tumor necrosis factor α and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J.Pharmacol.Exp.Ther. 283 918 PMID: 9353414
Juttler et al (2004) The cannabinoid dexanabinol is an inhibitor of the nuclear factor kappa B (NF-κB). Neuropharmacology 47 580 PMID: 15380375
If you know of a relevant reference for HU 211, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: HU 211, HU 211 supplier, NF-κB, NF-kappaB, NF-kB, inhibitors, inhibits, decreases, TNF-α, TNF-alpha, IL-6, NO, production, NMDA, antagonists, receptors, Nuclear, Factor, Kappa, B, Cytokine, Signaling, Signalling, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, HU211, Dexanabinol, NF-kB/IkB, 2861, Tocris Bioscience
Citations for HU 211
Citations are publications that use Tocris products.
Currently there are no citations for HU 211. Do you know of a great paper that uses HU 211 from Tocris? Please let us know.
Reviews for HU 211
There are currently no reviews for this product. Be the first to review HU 211 and earn rewards!
Have you used HU 211?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.